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116Limited information is available on the pathologic significance of human antigen R
(HuR) in prostate cancer (PCa). The main aim of this study was to clarify the relation-
ship between HuR expression andmalignant aggressiveness, outcome, and expres-
sion of cancer-related molecules in PCa. In vitro proliferation, colony formation, and
migration assays were performed on LNCaP and PC-3 cells. HuR expression was
knocked down (KD) using small interfering RNA. The relationships between HuR
expression and the expression of vascular endothelial growth factors (VEGFs), cyclo-
oxygenase (COX)-2, and heme oxygenase (HO)-1 were investigated in PCa cell
lines using Western blotting. On KD of HuR, cell proliferation and migration were
suppressed in both LNCaP and PC-3 cells, whereas expression of VEGF-A to -D and
COX-2was suppressed in PC-3 but not in LNCaP cells. In addition, expression of these
cancer-related factors was analyzed in 182 hormone-na€ıve PCa and 23 castration-
resistant prostate cancer (CRPC) human tissues in vivo. Cytoplasmic (C)-HuR expres-
sion was significantly higher in CRPC . hormone-na€ıve PCa . nontumoral cells.
C-HuR expression was positively associated with Gleason score, T stage, andmetas-
tasis, and it was considered to be a useful predictor of biochemical recurrence after
radical prostatectomy. C-HuR expression was correlated with COX-2 expression in
hormone-na€ıve PCa, and with the expression of VEGF-A, VEGF-C, and COX-2 in
CRPC tissues. Our results demonstrated that HuR plays important roles in determining
malignant aggressiveness and outcome in PCa, especially in androgen-
independent PCa cells, via the regulation of cell proliferation, migration, and expres-
sion of VEGF-A, -C, and COX-2. (Translational Research 2016;175:116–128)Abbreviations: BCR ¼ biochemical recurrence; COX ¼ cyclooxygenase; CRPC ¼ castration-
resistant prostate cancer; HO¼ heme oxygenase; HuR¼ human antigen-R; IRS¼ immunoreac-
tive score; KD ¼ knockdown; PCa ¼ prostate cancer; PSA ¼ prostate-specific antigen; RP ¼
radical prostatectomy; VEGFs ¼ vascular endothelial growth factors; WT ¼ wild type, Nagasaki University Graduate
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AT A GLANCE COMMENTARY
Mitsunari K, et al.
Background
Prostate cancer is one of the most common cancer
worldwide, and prognosis of castration-resistant
prostate cancer (CRPC) is poor despite various
treatments are performed. Relationships between
human antigen R (HuR) and clinicopathologic fea-
tures, prognosis, and malignant potential including
cancer cell proliferation, migration, vascular endo-
thelial growth factors (VEGFs), cyclooxygenase
(COX)-2, and heme oxygenase (HO)-1 in prostate
cancer are not clear.
Translational Significance
HuR played important roles for tumor growth, pro-
gression, and biochemical recurrence via regula-
tion of cell proliferation, migration, and COX-2
expression in androgen-na€ıve cancer cells. In
addition to these variables, HuR expression was
associated with VEGF-A and -C in androgen-
independent cells and CRPC.
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Prostate cancer (PCa) is one of the most commonly
diagnosed malignancies in Western countries.1 Tumor
growth, invasion, and dissemination of cancer cells
are regulated by various cancer-related genes and
molecules, and regulation of messenger RNA
(mRNA) decay is an essential mechanism for control-
ling their activities. Human antigen R (HuR) is a
member of the embryonic lethal abnormal vision-like
family of RNA-binding proteins.2 HuR is widely
expressed and is associated with posttranscriptional
regulation and stability of RNA.2,3 Previous reports
demonstrated that HuR can regulate mRNA
metabolism and protein expression of various cancer-
related molecules, such as vascular endothelial growth
factors (VEGFs), cyclooxygenase (COX)-2, and heme
oxygenase (HO)-1.4-7 HuR has been shown to play
important roles in tumor development, progression,
and outcome in multiple in vitro and in vivo
studies.7-11 However, little information is available
regarding HuR expression in PCa cell lines and
human PCa tissues.10,11 In addition, the relationships
between HuR expression and malignant potential,
tumor progression, and clinical outcome in patients
with PCa are not fully understood.Androgen deprivation therapy is recognized as an
effective treatment for patients with advanced PCa. In
addition, this therapy is given to patients that show
prostate-specific antigen (PSA) relapse after radical
prostatectomy (RP) and radiotherapy. Unfortunately,
almost all these patients progress to castration-
resistant prostate cancer (CRPC), which has poor
outcome and survival. Therefore, understanding the
detailed mechanisms of how androgen-sensitive cancer
cells develop into androgen-independent cells is essen-
tial for the improvement of outcomes for patients with
PCa. In fact, CRPC-related mechanisms and alternate
androgen receptor signaling pathways, such as amplifi-
cation, mutation, and/or hypersensitivity of androgen
receptors, have garnered much attention.12,13 In
addition, pathways independent of the androgen
receptor system have been suggested to play
important roles in malignant aggressiveness in
CRPC.13,14 However, pathologic characteristics in
CRPC remain unclear.
The main purpose of this study was to clarify the
following 3 points regarding HuR in PCa, using
in vivo and in vitro studies: (1) the correlation be-
tween HuR and cancer cell proliferation and inva-
sive potential; (2) the relationship between HuR
expression and malignant potential, pathologic fea-
tures, and outcome; and (3) the correlation between
HuR and expression of VEGF-A to -D, COX-2,
and HO-1. Our results demonstrated that HuR is
closely associated with malignant behavior and
outcome in both of androgen-dependent and -inde-
pendent PCa cells via the regulation of cancer cell
proliferation and migration. In addition, increased
expressions of VEGF-A, VEGF-C, and COX-2 by
upregulation of HuR expression are speculated to
be play crucial roles in pathologic characteristics
in androgen-independent PCa cells and CRPC
tissues.MATERIALS AND METHODS
Patient characteristics. The study cohort consisted of
182 men who were diagnosed with PCa at Nagasaki
University Hospital and 115 men who underwent RP
for organ-confined disease to accurately confirm
tumor growth using the Gleason score. The
clinicopathologic features are listed in Table. For
estimation of biochemical recurrence (BCR), the
mean (median/interquartile range) follow-up duration
was 37.1 (28/15–52) months. An additional cohort of
23 men diagnosed with CRPC was also investigated.
Furthermore, 80 specimens of prostate tissue free of
tumor as indicated by pathologic examination were
Table. Relationship between HuR expression and clinicopathologic features at diagnosis
Clinico-pathological features














Mean (SD), years 66.3 (7.8) 66.1 (8.3) 66.4 (7.3) 63.6 (6.3) 63.5 (6.0) 63.7 (6.6)
P value* 0.810 0.856
Serum PSA level
Mean (SD), ng/mL 99 (198) 77 (154) 119 (229) 10.6 (8.2) 9.6 (5.4) 12.2 (10.8)
P value* 0.110 0.110
Gleason score
Low (4–6) 35/19.2 23/65.7 12/34.3 36/31.3 24/66.7 12/33.3
Middle (7) 66/36.3 33/50.0 33/50.0 42/36.5 24/57.1 18/42.9
High (8–10) 81/44.5 30/37.0 51/63.0 37/32.2 13/35.1 24/64.9
P value* 0.015 0.021
T stage (RP tissues)
T1– 17/9.3 16/59.3 11/40.7 – – –
T2 (pT2) 68/37.4 42/61.8 26/38.2 74/64.3 48/64.9 26/35.1
T3 (pT3) 61/33.5 26/42.6 35/57.4 41/35.7 13/31.7 28/68.3
T4 (pT4) 26/14.3 2/7.7 24/92.3 0/0.0 0/0.0 0/0.0
P value* ,0.001 ,0.001
Metastasis
Absence 115/63.2 61/53.0 54/47.0 – – –
Presence 67/36.8 25/37.3 42/62.7 – – –
P value* 0.040 –
Abbreviations: HuR, human antigen R; n, numbers of patients; PSA, prostate-specific antigen; RP, radical prostatectomy; SD, standard devia-
tion.
Data given as number/percentage unless otherwise indicated.
*P value from chi-square test.
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chronic prostatitis lesions and they were evaluated for
HuR expression.
Cell culture and small interfering RNA transfection. Two
human PCa cell lines, LNCaP (androgen-independent)
and PC-3 (androgen-dependent), and a normal
prostate cell line (normal human primary prostate
epithelial cells) were purchased from the American
Type Culture Collection (Manassas, Va). Cells were
cultured in RPMI 1640 medium (Gibco; Life
Technologies) supplemented with 10% fetal bovine
serum and 50-mg/mL gentamicin (Gibco; Life
Technologies) at 37C in a humidified atmosphere
of 5% CO2 and 95% air. LNCaP and PC3 cells
were seeded at 5 3 105 cells per 100-mm dish.
After 24 hours, the cells were transfected with
20 nM of HuR small interfering RNA (siRNA)
using jet PRIME transfection reagent (Polyplus-
transfection Inc, NY) according to the
manufacturer’s protocol. HuR expression was
assessed by Western blot analysis. Stable HuR
knockdown (KD) clones were selected for use in
further experiments. Nonspecific effects were ruledout by using nonspecific control siRNA (Negative
Control siRNA, Qiagen).
MTT and colony formation assays. Relative numbers of
viable cells were determined using the MTTassay (Cell
Proliferation Kit I [MTT]; Roche). LNCaP and PC3
cells were seeded in each well of a 96-well plate and
were allowed to adhere and spread for 24 hours. MTT
labeling reagent was added to each well, and the
cultures were incubated for 4 hours at 37C.
Solubilization solution was added, and the cells were
incubated in a humidified atmosphere overnight. Cell
counts were determined by measuring the absorbance
at 550 nm.
To confirm the MTTassay results, a colony formation
assay was performed. Briefly, wild-type (WT) and HuR-
KD cells (53 103 per well) were seeded in 6-well plates
with complete culture medium. After 14 days of incuba-
tion at 37C in a 5% CO2 humidified atmosphere,
colonies were stained with Giemsa solution. The num-
ber of colonies was counted using a light microscope.
Colonies with .50 cells were scored.
Gap closuremigration assay. Cells (2.1 3 104) were
seeded in a 2-well culture insert (ibidi GmbH)
Fig 1. HuR expression in prostate cancer cell lines and human tissues. (A) Western blots of HuR expression in the
androgen-independent PC-3 cell line than in the androgen-sensitive LNCaP cell line and a normal human primary
prostate epithelial cell line. GADPH was used for normalization. (B) Western blots of cytoplasmic (C)-HuR and
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incubated for 24 hours. A cell-free gap (500 mm in
width) was created after removing the culture
insert, and the medium was replaced with RPMI
containing 10% fetal bovine serum. LNCaP cells
were incubated for 24, 48, and 72 hours, and PC3
cells were incubated for 24 and 48 hours. Cell
migration was evaluated by measuring the gap
under a microscope.
Western blot analysis. Western blot analysis was per-
formed as described previously.15 Cultured cells were
harvested by scraping. Cell lysates were prepared in
ice-cold hypotonic cell lysis buffer containing
protease inhibitors. Aliquots of total cellular lysate
(40–50 mg per lane) were electrophoresed on sodium
dodecyl sulfate (SDS)–polyacrylamide gels and
transferred to nitrocellulose membranes. After
blocking with 5% nonfat milk in Tris-buffered saline
containing 0.1% Tween 20 (TBS-T) for 1 hour at
room temperature, the membrane was incubated with
primary antibody overnight at 4C. After washing
with TBS-T 3 times, the membrane was incubated
with the appropriate secondary antibody for 1 hour at
room temperature. Specific protein bands were
detected by ECL Prime.
Nuclear and cytoplasmic fractionation. Cells were
grown on 100-mm dishes until 75% confluence,
washed with cold phosphate-buffered saline, and
cellular fractions were isolated using the subcellular
protein fractionation kit (Thermo Scientific Pierce)
as per the manufacturer’s instructions. Nuclear
and cytoplasmic fractions were analyzed for HuR
protein expression by Western blotting as described
previously.16 The relative levels of cytoplasmic
and nuclear HuR expression were normalized to b
actin and HDAC1 (Santa Cruz) expression,
respectively.
Immunohistochemical and immunofluorescence
staining. Immunohistochemical staining for HuR was
performed using formalin-fixed, paraffin-embedded
specimens. Paraffin sections (5-mm thick) were
deparaffinized and rehydrated. After deparaffinization,nuclear (N)-HuR expression in the PC-3, LNCaP, and nonc
normalization of C-HuR and N-HuR expression, respective
expression (C and E) and nuclei counterstained with DAPI
(C) was confirmed to be higher than that in the LNCaP cell li
PCa and nontumoral prostate tissue sections immunohistoch
staining was mainly detected in the nuclei in nontumoral hea
PCa tissues (I and J), C-HuR expression was higher than tha
of C-HuR expression in hormone-na€ıve PCa tissues (arrows i
sues showed highest staining for C-HuR, and some specime
titation of C-HuR and N-HuR. Data represent the mean ratio
castration-resistant prostate cancer; GAPDH, glyceraldehyd
R; PCa, prostate cancer.
=antigen retrieval was performed at 100C for
15 minutes in 0.01-M sodium citrate buffer (pH 6.0).
Blocking of endogenous peroxidase was performed
using 3% hydrogen peroxide for 30 minutes. All
sections were incubated overnight with anti-HuR
(Santa Cruz) at 4C and then treated with peroxidase-
labeled polymer using the EnVision1 system
(DakoCytomation) for 60 minutes. Peroxidase was
visualized using a liquid 3,30-diaminobenzidine
tetrahydrochloride substrate kit (Invitrogen). Then, the
sections were counterstained with hematoxylin.
Nuclear and cytoplasmic HuR expressions were
evaluated separately according to a previous report.17
Briefly, expression was scored using the following
scale: 0, no staining; 1, weak and/or focal staining
(,10% of cells); 2, moderate or strong staining
(10%–50% of cells); and 3, moderate or strong
staining (.50% of cells). Scores 0 and 1 were judged
as low expression, and scores 2 and 3 were judged as
high expression. Staining with other antibodies was
performed as described in our previous reports.18-20 In
short, antigen retrieval was performed in 0.01-M
sodium citrate buffer (pH 6.0) for all antibodies. The
primary antibodies were purchased from
DakoCytomation (anti-Ki-67), Santa Cruz
Biotechnology (anti-VEGF-A and anti-VEGF-B),
Zymed Laboratories (anti-VEGF-C), R&D Systems
(anti-VEGF-D), Immuno-Biological Laboratories Co,
Ltd (anti-COX-2), and Enzo Life Sciences Inc (anti-
HO-1). All specimens were assessed using the
immunoreactive score (IRS), which was calculated by
multiplying the staining intensity (grade 0 5 none,
1 5 weak, 2 5 moderate, and 3 5 strong) by the
percentage of positively stained cells (0, ,5.0%; 1,
5%–25%; 2, 26%–50%; and 3, .51%). To determine
cancer cell proliferation, the proliferation index (PI)
was used to represent the percentage of Ki-67-positive
cells. The positive and negative controls and blocking
peptide competition assay have been described in our
previous reports.18-22
Immunofluorescence staining was performed as
described previously.16 Briefly, cells were grown onancer cell line. b-Actin and HDAC1 were used for
ly. (C–F) Fluorescence microscopic images of HuR
(D and F). C-HuR expression in the PC-3 cell line
ne (E). (G–K) Representative micrographs of human
emically stained for HuR expression. HuR immuno-
lthy (G) and prostatitis tissues (H). In hormone-na€ıve
t in nontumoral tissues (G andH). (J) Heterogeneity
ndicate strongly stained cancer cells). (K) CRPC tis-
ns showed low N-HuR expression. (L andM) Quan-
of positively stained cells in human tissues. CRPC,
e 3-phosphate dehydrogenase; HuR, human antigen
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line and fixed by incubation in a 1:1 methanol:acetone
solution at 4C for 30 minutes. The cells were rinsed
and hydrated with TBS-T and then incubated at room
temperature for 1 hour in 5% milk solution in TBS-T
to block nonspecific binding, followed by incubation
at room temperature for 1 hour with rabbit anti-HuR
polyclonal antibody (Santa Cruz). Next, the cells were
incubated with fluorescein isothiocyanate–conjugated
goat anti-rabbit antibody for 1 hour and washed 3 times
(15 minutes each) with TBS-T. The nuclei were
counterstained with mounting medium containing
40,6-diamidino-2-phenylindole (DAPI). Images were
captured on a fluorescence microscope (Leica TCS
STED Confocal Microscope; Leica Microsystems).
Statistical analyses. Data are expressed as the mean
and standard deviation, unless otherwise stated. The
Student’s t test or Mann-Whitney U test was
performed for continuous variables. The chi-square
test and the Scheffe test were used for categorical
comparisons and for multiple comparisons,
respectively. In survival analysis, Kaplan-Meier curves
and log-rank tests were used, and Cox proportional
hazards model multivariate analysis was performed.
All statistical tests were 2-sided, and significance was
defined as P , 0.050. All statistical analyses were
performed on a personal computer using the StatView
for Windows statistical package (version 5.0; Abacus
Concepts).
RESULTS
HuR expression in PCa cell lines and human
tissues. HuR expression was higher in both LNCaP
and PC-3 cells than in control cells as indicated by
Western blot analysis, but the expression level was
higher in PC-3 than in LNCaP cells (Fig 1, A).
Cellular fractionation revealed that the higher
expression in PC-3 cells could be mainly attributed to
cytoplasmic (C-HuR) expression (Fig 1, B). HuR
expression in the cancer cell lines as detected by
fluorescence microscopy is shown in Fig 1, C–F.
C-HuR expression was higher in PC-3 cells (Fig 1, C)
than in LNCaP cells (Fig 1, E).
In vivo data are presented in Fig 1,G–K. In human tis-
sues, nontumoral glands showed moderate-to-strong
nuclear (N-HuR) expression and absent-to-weak
C-HuR expression (Fig 1, G). In prostatitis tissues, no
significant change or specific pattern of N-HuR and
C-HuR expression as compared to nontumoral glands
without prostatitis was observed (Fig 1, H). In hor-
mone-na€ıve PCa tissues, moderate-to-strong N-HuR
expression was detected (Fig 1, I). However, the inten-
sity of C-HuR expression in hormone-na€ıve PCa tissues
was clearly stronger than that in nontumoral cells(Fig 1, G and H). In addition, C-HuR expression was
heterogeneous in hormone-na€ıve PCa tissues
(Fig 1, J). High N-HuR expression was observed in
91.3% (73/80) and 84.1% (153/182) of nontumoral
and hormone-na€ıve PCa tissues, respectively. In
contrast, 19 of 80 (23.4%) nontumoral tissues and 96
of 182 (52.7%) hormone-na€ıve PCa tissues showed
high expression of C-HuR. Thus, although no signifi-
cant difference was observed in N-HuR expression be-
tween nontumoral and hormone-na€ıve PCa tissues
(P5 0.120), C-HuR expression was significantly higher
in hormone-na€ıve PCa tissues (P , 0.001) than in non-
tumoral prostate glands. In CRPC tissues, strong stain-
ing for HuR was observed in the cytoplasm (Fig 1, K).
Finally, of the 23 CRPC samples examined, 6 (26.1%)
and 18 (78.3%) patients were judged as having high
expression of N- and C-HuR, respectively. As shown
in Fig 1, L, C-HuR expression was significantly higher
(P 5 0.020) in CRPC than in hormone-na€ıve PCa tis-
sues. In contrast, N-HuR expression was significantly
lower (P, 0.001) in CRPC than in nontumoral and hor-
mone-na€ıve PCa tissues (Fig 1, M).
Correlation of HuR expressionwith pathologic features in
hormone-na€ıve PCa tissues. We first analyzed the rela-
tionship between HuR expression and clinicopathologic
features at diagnosis using needle biopsy specimens. As
listed in Table, C-HuR expression was significantly
associated with the Gleason score (P 5 0.015), clinical
T stage (P , 0.001), and presence of metastasis at
diagnosis (P 5 0.040), but not with age (P 5 0.810)
and serum PSA level (P 5 0.110). When we
performed a similar analysis for RP specimens to more
accurately clarify the relationships, the positive
relationships with the Gleason score (P 5 0.021) and
T stage (P , 0.001) were confirmed (Table). However,
N-HuR expression was not associated with age
(P 5 0.243), serum PSA level (P 5 0.296), Gleason
score (P 5 0.114), clinical T stage (P 5 0.262), or
presence of metastasis (P 5 0.698) in biopsy
specimens at diagnosis. In addition, no significant
relationship between N-HuR and clinicopathologic
features was found in the RP specimens.
Correlation of HuR expression with proliferation and
migration. On stable transfection of HuR siRNA in
LNCaP and PC-3 cells, HuR expression was decreased
for at least 96 hours, indicating high silencing efficiency
(Fig 2, A and B). As shown in Fig 2, C and D, HuR-KD
led to decreased cell proliferation in both LNCaP and
PC-3 cells. Similarly, in both cell lines, colony counts
for HuR-KD cells were significantly lower
(P , 0.001) than those for WT cells (Fig 2, E–H).
In LNCaP cells, the wound closure rate was signifi-
cantly lower (P , 0.001) in WT cells than in HuR-
KD cells after 72 hours (Fig 3, A and B). In PC-3 cells,
Fig 2. Correlation of HuR expression with proliferation. (A and B) Western blot showing HuR expression at 48 and
96hafterKDbysiRNAtransfection inLNCaP (A) andPC-3 cells (B). (C andD)Growthcurvesofwild-type (WT)and
HuR KD cells in LNCaP (C) and PC-3 cells (D) as determined by MTTassay; absorbance was measured at 550 nm.
There was signficant difference regarding cell prolifetaion between wild type cells and HuR-KD cells in both LNCaP
and PC-3 cells (*). (E–H) Colony formation assay (E andG) in LNCaP (E and F) and PC-3 cells (G andH). (I) PI,
determined as the percentage ofKi-67-positive cells, of CRPC and hormone-na€ıve PCa tissues. (J) C-HuR expression
is positively correlated with PI in hormone-na€ıve PCa and CRPC tissues. CRPC, castration-resistant prostate cancer;
HuR, human antigen R; KD, knockdown; PCa, prostate cancer; siRNA, small interfering RNA.
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Fig 3. Correlation of HuR expression with migration. The gap closure assay was used to evaluate migration inWT
and KD LNCaP (A and B) and PC-3 cells (C and D). (A and C) Representative images of the assay. (B and D)
Quantitation of migration at 24, 48, and 72 h after KD using siRNA for LNCaP and at 24 and 48 h for PC-3.
HuR, human antigen R; KD, knockdown; siRNA, small interfering RNA; WT, wild-type.
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gree of wound closure than HuR-KD PC-3 cells after
48 hours (Fig 3, C and D).
The in vivo study showed that PIs in CRPC tissues
(24.8/7.1%) were significantly higher (P , 0.001)
than those in hormone-na€ıve PCa tissues (9.4/6.3%,
Fig 2, I). However, in hormone-na€ıve PC tissues,
the PI was significantly higher (P , 0.001) in tissues
with high C-HuR expression (10.8/5.9) than in those
with low HuR expression (7.9/6.4, Fig 2, J). A
similar positive correlation between C-HuR expres-
sion and PI was detected in CRPC tissues
(P 5 0.037, Fig 2, J).
Correlation of HuR expression with VEGFs, COX-2, and
HO-1 in vivo and in vitro. In the androgen-independent
PC-3 cell line, KD of HuR expression led to
decreased expression of VEGF-A, -B, -C, and -D, and
COX-2, but not HO-1, as compared to the negative
control (Fig 4). In contrast, no significant effect of
HuR KD was detected in the androgen-dependent
LNCaP (Fig 4).The IRSs of HuR-related molecules in the PCa tissues
are shown in Fig 5. They were significantly higher in
CRPC than in hormone-na€ıve PCa tissues (VEGF-A,
P , 0.001; VEGF-C, P 5 0.005; VEGF-D,
P 5 0.043; COX-2, P , 0.001; and HO-1,
P 5 0.044), except for VEGF-B. In hormone-na€ıve
PCa tissues, C-HuR expression was significantly associ-
ated with COX-2 expression (P 5 0.025), but not with
VEGF-A, -B, -C, and -D or HO-1 expression. In
CRPC tissues, C-HuR expression was positively associ-
ated with the expression of VEGF-A, VEGF-C, and
COX-2, but not with that of VEGF-B, VEGF-D, or
HO-1 (Fig 5, A–F).
Predictive value of HuR expression for BCR after RP. We
analyzed the prognostic value of C-HuR expression
for BCR in 115 patients treated by RP. Kaplan-Meier
survival curves indicated that C-HuR expression was
significantly associated with BCR-free survival
(P 5 0.028, Fig 6); however, it was not identified as
an independent predictor in multivariate analysis
Fig 4. Correlation of HuR expression with VEGFs, COX-2, and HO-1 in vitro. Western blots showing expression
of VEGF-AD, COX-2, and HO-1 in WT, KD, and siRNA control cells of the PC-3 and LNCaP cell lines. GAPDH
was used for normalization. COX-2, cyclooxygenase; HO, heme oxygenase; GAPDH, glyceraldehyde 3-phos-
phate dehydrogenase; HuR, human antigen R; KD, knockdown; siRNA, small interfering RNA; VEGF, vascular
endothelial growth factor.
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3.24, P 5 0.282). In contrast, Kaplan-Meier survival
curves showed that N-HuR expression was not a
significant predictor for BCR (P 5 0.976).
DISCUSSION
Several previous studies have investigated the
pathologic significance and prognostic value of HuR
expression in patients with PCa, and they showed that
C-HuR expression was higher in cancer cells than in
nontumoral cells.11,12 These studies also showed a
trend toward reduced N-HuR expression in PCa cells
as compared to noncancerous cells11,12 Our results
support these findings. In addition, we identified a
significant relationship between C-HuR expression
and the Gleason score and T stage in PCa specimens
obtained by RP. These results were as expected
because C-HuR expression has been reported to be
significantly associated with malignant potential,
tumor growth, and cancer cell invasion in various
types of cancers.7-10 One study of 104 PCa specimens
reported that C-HuR expression was not significantly
associated with either Gleason score or T stage
(P 5 0.177 and P 5 0.675, respectively).11 We
speculate that these conflicting results can be attributed
to differences in the antibodies and evaluation methodsused, and in pathologic features of the study population.
To our knowledge, this is the first study to demonstrate a
positive correlation between C-HuR expression and the
presence of metastasis in patients with PCa, high-
lighting that there is value in continuing research into
the roles of HuR in metastatic processes in PCa cells.
Next, we analyzed the effects of HuR on cell prolifer-
ation and migration in PCa cells to clarify the detailed
mechanism underlying the pathologic role of HuR. In
the in vitro study, suppression of HuR expression led to
downregulation of cancer cell proliferation, colony for-
mation, and migration in androgen-sensitive PCa cells.
Although the present study is the first to report on the
relationship between HuR expression and these cancer-
related characteristics in a PCa cell line, previous reports
in other malignant cells showed that HuR was positively
associated with cell proliferation and tumor develop-
ment.23,24 Thus, our in vitro results are concordant
with these findings and with our in vivo data. Similar
positive correlations were detected in androgen-
independent PCa cells and CRPC tissues. We speculate
that HuR stimulates malignant aggressiveness by
increasing cancer cell proliferation and migration in
PCa cells, regardless of androgen dependence.
KD of HuR expression did not alter the expression of
any cancer-related molecules in androgen-sensitive PCa
Fig 5. Correlation of HuR expression with VEGFs, COX-2, and HO-1 in vivo. In human hormone-na€ıve PCa tis-
sues, the IRS of C-HuR was associated with the IRS of cyclooxygenase (COX)-2, but not with any other IRSs
(A–F). In CRPC tissues, the IRS of C-HuR was positively associated with the IRSs of vascular endothelial growth
factor (VEGF)-A (A), VEGF-C (C), and COX-2 (E). Number represent the mean/SD, bars are the mean 1 SD.
CRPC, castration-resistant prostate cancer; HO, heme oxygenase; HuR, human antigen R; IRS, immunoreactive
score; PCa, prostate cancer; SD, standard deviation.
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Fig 6. Predictive value of HuR expression for BCR after RP. Kaplan-
Meier survival curves showing that patients with high cytoplasmic
HuR expression had a worse outcome than thosewith lowHuR expres-
sion in terms of BCR after RP (log rankP5 0.028). BCR, biochemical
recurrence; HuR, human antigen R; RP, radical prostatectomy.
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na€ıve PCa tissues, except for COX-2 expression.
Briefly, in hormone-na€ıve PCa cells, HuR expression
was not associated with expression of VEGF-A to -D
or HO-1 in vivo or in vitro. However, our results showed
that HuR expression is positively associated with
expression of VEGF-A, -C, and COX-2 in androgen-
independent PCa cells both in vivo and in vitro.
VEGF-A mRNA expression has been reported to be
higher in PC-3 cells than in LNCaP cells.25 In addition,
VEGF-A staining intensity was reported to be signifi-
cantly higher in CRPC (6.7 6 0.32) than in hormone-
na€ıve PCa (4.06 0.33, P, 0.001) tissues.26 Our results
are concordant, and we speculate that VEGF-A expres-
sion is increased during the progression to androgen in-
dependence. Furthermore, we hypothesized that HuR
expression would be positively associated with
VEGF-A expression in PCa cells in vivo and in vitro
because HuR has been reported to induce VEGF-A in
several cancers.7,9 Contrary to our expectations, HuR
expression was not significantly associated with
VEGF-A expression in either LNCaP cells or hor-
mone-na€ıve PCa tissues. On the other hand, positive
correlations were observed in both PC-3 cells and
CRPC tissues, as expected. The prior study that showed
that increased VEGF-A expression was regulated by the
activation of HuR was performed using an androgen-
independent PCa cell line (DU145).27 We speculate
that the mechanism by which VEGF-A expression is
regulated by HuR is induced and becomes significant
during the switch to androgen-independent PCa.
Regarding VEGF-C, several reports showed that its
mRNA and protein levels were remarkably higher in
PC-3 than in LNCaP cells,25,28 which is consistent
with our results. However, the expression level ofVEGF-C in CRPC tissues was unclear. In addition, there
were no reports on the relationship between HuR and
VEGF-C in PCa, including androgen-independent PCa
cells and CRPC tissues. Based on our results, we sug-
gest that VEGF-C expression is increased during the
progression to androgen independence and is regulated
by HuR expression in CRPC tissues, but not in hor-
mone-na€ıve PCa tissues.
In contrast to VEGF-A and -C, few data are available
on the pathologic roles and clinical significance of
VEGF-B and -D in PCa, although several studies have
been performed.29,30 In particular, little information is
available on VEGF-B expression in PCa. Furthermore,
correlations with HuR expression in PCa have not
been reported. In LNCaP cells, VEGF-D expression
was decreased on KD of HuR. In addition, the IRSs of
VEGF-D were significantly higher in CRPC than in hor-
mone-na€ıve PCa. However, VEGF-D expression was
not associated with HuR expression in androgen-
independent PCa cells or human CRPC tissues.
Together, these results suggest that VEGF-B may play
a minimal role in carcinogenesis and malignant aggres-
siveness in PCa. We speculate that the pathologic activ-
ities of VEGF-D depend on the status of the cancer cells
and the tumor environment.
COX-2 is a well-known factor that affects malignant
aggressiveness and worsens the prognosis in PCa.31
Several investigators have reported that HuR expression
is positively associated with COX-2 expression in hor-
mone-na€ıve PCa cells,10,11 similar to our results.
Because COX-2 inhibitors suppress disease progression
in patients with CRPC, it has been suggested that
COX-2 plays important roles in malignant behavior in
androgen-independent PCa.13 However, little informa-
tion is available regarding the pathologic roles of
COX-2 expression in CRPC tissues. To our knowledge,
our study is the first to demonstrate that COX-2 expres-
sion is significantly higher in CRPC tissues than in hor-
mone-na€ıve PCa tissues. In addition, we showed a
significant correlation between HuR expression and
COX-2 expression in androgen-independent PCa cells.
Based on these data, we suggest that HuR plays an
important role in malignant behavior by regulating
COX-2 expression in androgen-independent PCa cells
and CRPC tissues. Seemingly contradictory results
were obtained from our in vitro study: KD of HuR
expression led to suppression of COX-2 expression in
androgen-independent, but not in androgen-sensitive
PCa cells. Unfortunately, our study design did not allow
us to elucidate the reason behind this observation. How-
ever, other investigators have reported that phorbol
ester–induced COX-2 overexpression was suppressed
by leptomycin B, an HuR inhibitor, in PC-3 cells; how-
ever, no such trend was observed in LNCaP cells.11
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size that regulation of COX-2 expression by HuR
expression in androgen-independent PCa cells differs
from that in androgen-sensitive PCa cells, and that the
HuR-mediated COX-2 pathway is stronger in CRPC tis-
sues than in hormone-na€ıve PCa tissues. Relationships
between HuR expression and malignant aggressiveness
regulated by COX-2 are key mechanisms for progres-
sion in various types of malignancies.32-34 Future
studies will have to elucidate these relationships and
their relevance in PCa.
In our in vivo study, N-HuR expression was not asso-
ciated with any of the parameters investigated,
including clinicopathologic features, outcome, and
expression of cancer-related molecules. N-HuR seems
to play a minimal role in determining the malignant
aggressiveness of various cancers. However, it has
been reported to be important in malignant behavior
and prognosis in breast cancer.35 As a result, the clinical
significance and pathologic role of N-HuR have been
debated. Interestingly, N-HuR expression tended to be
absent in CRPC tissues in our study. Unfortunately, no
data are presently available regarding N-HuR expres-
sion in CRPC. Several investigators have shown that
androgens regulate the level and subcellular shuttling
of HuR. Specifically, dihydrotestosterone treatment
increased C-HuR, but decreased N-HuR in Jurkat and
HepG2 cells.36,37 Furthermore, the relapse rate was
significantly higher in PCa patients with loss of
N-HuR expression (P 5 0.04) than in those with
normal expression.11 Thus, the distribution of HuR in
PCa cells may be influenced by anti-androgen therapy,
and loss of N-HuR expression leads to resistance to
androgen-deprivation therapy. We strongly suggest
that further in vivo and in vitro studies be performed
to confirm this hypothesis. Numerous investigators
believe that understanding the pathologic mechanism
andmolecular changes in CRPC is important to improve
the outcome and prolong the survival period, and further
detailed discussion on the pathologic characteristics of
PCa is important.38,39ACKNOWLEDGMENTS
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